Brief: Aelis Farma Announces The Final Analysis Of Phase 2B Clinical Trial In Cannabis Use Disorder With AEF0117

Aelis Farma SA

26/03/2025 17:35

March 26 (Reuters) - Aelis Farma SA AELIS.PA:

AELIS FARMA ANNOUNCES THE FINAL ANALYSIS OF THE LANDMARK PHASE 2B CLINICAL TRIAL IN CANNABIS USE DISORDER (CUD) WITH THE CB1-SSI AEF0117

AELIS FARMA SA - AEF0117 WELL-TOLERATED WITH NO SAFETY CONCERNS IDENTIFIED

Source text: ID:nBw1SPbLRa

Further company coverage: AELIS.PA

 (((( Reuters.Briefs@thomsonreuters.com ;));))